Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (211-220 of 227) with videos related to

Pageof 23
Sort By:
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|March 5, 2025
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus VulgarisBillal Tedbirt, Estelle Houivet, Maud Maho-Vaillant, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Journal of the American Academy of Dermatology|November 8, 2011
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of expertsDedee F Murrell, Benjamin S Daniel, Pascal Joly, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of expertsDedee F Murrell, Branka Marinovic, Frederic Caux, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
Eclinicalmedicine|July 15, 2024
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Pageof 23

Showing results (211-220 of 227) with videos related to

Sort By:
Pageof 23
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|March 5, 2025
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus VulgarisBillal Tedbirt, Estelle Houivet, Maud Maho-Vaillant, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Journal of the American Academy of Dermatology|November 8, 2011
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of expertsDedee F Murrell, Benjamin S Daniel, Pascal Joly, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of expertsDedee F Murrell, Branka Marinovic, Frederic Caux, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
Eclinicalmedicine|July 15, 2024
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Pageof 23